There are currently 28 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757
Recruiting
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Register for Updates
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/21/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease
Register for Updates
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
06/20/2024
Locations: MD First Research - Chandler, Chandler, Arizona +75 locations
Conditions: Alzheimer's Disease
Register for Updates
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
NCT05655195
Recruiting
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the... Read More
Gender:
All
Ages:
Between 65 years and 100 years
Trial Updated:
05/30/2024
Locations: Massachusetts Institute of Technology, Cambridge, Massachusetts
Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Register for Updates
Wake Forest Alzheimer's Disease Clinical Core
NCT03140865
Recruiting
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
05/30/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Register for Updates
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
All
Ages:
Between 35 years and 85 years
Trial Updated:
05/30/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +18 locations
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
Register for Updates
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
05/24/2024
Locations: MD First Research - Chandler, Chandler, Arizona +48 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Register for Updates
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
NCT05804383
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
05/16/2024
Locations: Yale University, New Haven, Connecticut +1 locations
Conditions: Alzheimer's Disease
Register for Updates
New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study
NCT04426539
Recruiting
New IDEAS is an observational, open-label, longitudinal cohort study designed to address the requirements of the CED provisions of the NCD on beta-amyloid PET. Building on the initial Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Full list of Active Sites and Imaging Facilities, Philadelphia, Pennsylvania
Conditions: Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Register for Updates
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240
Recruiting
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/13/2024
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida +2 locations
Conditions: Alzheimer's Disease
Register for Updates
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
NCT05040217
Recruiting
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
05/07/2024
Locations: University of California - San Diego, La Jolla, California +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
NCT05596994
Recruiting
The purpose of this research study is to investigate the effect of a light treatment on sleep, memory and brain function. In people with mild cognitive impairment (MCI) and Alzheimer's disease, sleep-wake disturbance is evident in up to 60% of patients. This can be caused by disruption of circadian rhythms and may affect our health and well-being. Circadian rhythms are the natural cycle of physical, mental, and behavior changes that the body goes through in a 24-hour cycle. Circadian rhythms are... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
05/02/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Register for Updates